In total, 96 adenomas and in situ carcinomas were analyzed for mutations in 11 genes (APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53). This evidence concerns the gene TP53 and in situ carcinoma.